Programmed death 1 expression in cancer and infection: tissue versus periphery PD-1:PD-L1 blockade as host-directed therapy Anti-PD-1:PD-L1/2 therapy: improved efficacy with acceptable toxicity Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for combination with other immunotherapies Conc...
Immune checkpoint blockade (ICB) therapy, particularly antibodies targeting the programmed death receptor 1 (PD-1) and its ligand (PD-L1), has revolutionized cancer treatment. However, its efficacy as a standalone therapy remains limited. Although ICB therapy in combination with chemotherapy shows pr...
anti-PD-1 antibody. These unique features of Met@Man-MPs contribute to boost anti-PD-1 antibody therapy, improving anticancer efficacy and long-term memory immunity after combination treatment. Our results support Met@Man-MPs as a potential drug to improve tumor resistance to anti-PD-1 therapy....
We analyzed the expression of CXCL9 in blood samples from patients who received anti-PD-1 therapy and evaluated its correlation with clinicopathological characteristics and treatment outcomes. Based on the results of Cox regression analysis, a nomogram was established for predicting HCC response to anti...
PD-1/PD-L1 activity in the CRC microenvironment Monoclonal antibodies in CRC treatment Combination of PD-1 inhibitors and mAbs for cancer therapy Administration of inflammatory agents for CRC therapy Clinical trials and challenges Conclusions Funding Availability of data and materials Ethics approval and...
Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disor...
Furthermore, syngeneic model mice were treated with sh-METTL14 andan anti-PD-1 antibody to observe the effect of METTL14 on immunotherapy. Flow cytometry and immunohistochemical (IHC) staining were used to detect CD8 expression. RIP and MeRIP were performed to assess the relationship between ...
Journal of Hematology & Oncology https://doi.org/10.1186/s13045-020-00926-x (2020) 13:99 RESEARCH Open Access CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer Jian Wang1† , Ruiguang Zhang1†, Zhenyu Lin1, Sheng...
PD-1 therapy, followed for 6 months: 17 responded to therapy, whilst 11 did not. Proportions of activated and proliferating CD8+T cells and of mucosal-associated invariant T (MAIT) cells are significantly higher in responders, prior to and throughout therapy duration. MAIT cells from responders...
Journal of Hepatocellular Carcinoma Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils Pei Wang1,2,*, Ming-Hao Xu3,*, Wen-Xin X...